AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

INSM · NASDAQ · Biotechnology

Insmed (INSM)

Commercializes rare pulmonary disease medicines while developing pulmonary, antibody and gene therapies.

$120.82

After hours+0.03 (+0.02%)

At close$120.79(−0.17%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	79	84	76	90	93	104	93	107	142	264	306	425
Cost of revenue	17	18	17	21	21	26	21	28	29	44	50	67
Gross profit	62	65	58	69	72	78	72	79	113	220	256	358
	210	244	204	358	286	309	320	392	479	469	457	360
Research & development	109	137	121	147	151	180	153	177	186	255	209	210
	91	90	93	107	119	143	148	155	186	212	247	247
General & administrative	91	90	93	107	119	143	148	155	186	212	0	247
Other expenses	10	17	−11	105	16	−14	20	60	106	2	0	−98
Operating income	−148	−178	−146	−289	−213	−230	−248	−313	−366	−250	−200	−2
	−11	−7	−11	−11	−6	−4	−8	−8	−3	−77	38	−10
Interest income	11	10	9	10	17	17	14	13	18	15	12	0
Interest expense	20	21	21	21	21	22	22	21	20	21	20	20
Other non-operating income	−8	−13	−9	−9	−14	−16	−12	−12	−16	58	−58	−10
Income before tax	−158	−185	−157	−300	−220	−234	−256	−320	−369	−327	−162	−11
Income tax expense	1	1	1	1	1	1	1	1	1	2	1	2
Net income from continuing operations	−159	−186	−157	−301	−221	−236	−257	−322	−370	−328	−164	−13
Net income	−159	−186	−157	−301	−221	−236	−257	−322	−370	−328	−164	−13
EPS, basic	−$1.11	−$1.28	−$1.06	−$1.94	−$1.27	−$1.32	−$1.42	−$1.70	−$1.75	−$1.54	−$0.76	−$0.06
EPS, diluted	−$1.11	−$1.28	−$1.06	−$1.94	−$1.27	−$1.32	−$1.42	−$1.70	−$1.75	−$1.54	−$0.76	−$0.06
Weighted average shares, basic	143	145	148	155	174	179	181	189	211	214	215	217
Weighted average shares, diluted	143	145	148	155	174	179	181	189	211	214	215	217
EBITDA	−137	−163	−134	−277	−196	−212	−233	−297	−346	−302	−136	14
Depreciation & amortization	3	3	3	3	3	3	3	4	4	6	6	5
EBIT	−139	−165	−137	−280	−199	−214	−236	−301	−350	−308	−142	9